Legend Biotech Corporation (NASDAQ: LEGN) saw its shares fall approximately 9 to 10% after reporting first-quarter 2026 results that disappointed investors on profitability. The decline came despite CARVYKTI net trade sales rising
More
Sanofi has returned to France as an Official Health Partner of the Special Olympics Unified Football World Cup, reinforcing its commitment to inclusive sport and public health awareness. The French pharmaceutical giant
More
Kelun has announced that its phase 3 OptiTROP-Lung06 study successfully met its primary endpoint in a significant win for its antibody-drug conjugate pipeline. The Chinese trial evaluated sac-TMT in combination with Merck’s
More
Veradermics has released topline results from a phase 2 study of its lead drug VDPHL01, an extended-release oral formulation of minoxidil, in women with pattern hair loss. The New Haven, Connecticut-based biotech’s
More
Johnson and Johnson has now delivered five consecutive quarters of at least 6% revenue growth, demonstrating remarkable resilience in the face of significant headwinds. The pharmaceutical giant’s immunology portfolio absorbed a serious
More
Gilead Sciences Canada has taken home a Bronze Lion at Cannes for its creative HIV prevention campaign built around LGBTQIA+ community identity. The campaign, titled Animal Attraction, was developed in partnership with
More
Merck has secured FDA approval for Lipfendra, its internally developed cholesterol-lowering drug, marking a significant milestone in cardiovascular medicine. Lipfendra, known scientifically as enlicitide, is a macrocyclic peptide that becomes the first
More
CG Life and its 24/364 platform have officially launched the inaugural 24/364 Rare Disease Film Festival, a first-of-its-kind cultural event dedicated to rare disease storytelling. The festival aims to amplify the voices
More
Novo Nordisk and biosimilar developer Alvotech are both contending with renewed regulatory pressure over manufacturing practices at facilities with troubled inspection histories. The U.S. Food and Drug Administration this week disclosed concerns
More
Novartis has secured traditional FDA approval for Fabhalta, also known as iptacopan, to slow kidney function decline in adults with primary immunoglobulin A nephropathy. The approval targets adults with IgAN who are
More